Pharma chameleon

The digital and AI shifts reshaping pharma

Digital capability is now a prerequisite for transformation across the pharma value chain, with core platforms expected to operate as connected ecosystems rather than standalone tools.

For organisations that have done the foundational work, AI amplifies this shift – turning clean, integrated data into predictive insights, automation and accelerated decision-making. But the inverse is equally true. AI also exposes weak foundations, amplifying poor data quality and increasing risk for organisations with weak digital foundations.

This widening maturity gap demonstrates how leaders are separating from followers, not through isolated pilots, but through sustained, enterprise-wide capability building. AI is no longer a future differentiator; it is the lens through which digital maturity is being measured today.

AI’s value in pharma emerges most clearly when applied within connected, well-governed environments, enhancing core systems for better decision-making and risk management at scale.

In compliance, AI enables a shift from reactive to predictive quality in environments where strong data integrity, traceability and validation practices meet emerging regulatory expectations, such as the draft EU GMP Annex 22.

In R&D, AI accelerates insight generation and informed prioritisation, dependent on harmonised and traceable data across systems.

In supply chains, it strengthens forecasting and reliability but relies on consistent master data and processes.

In each case, AI does not remove the need for strong operational discipline – it reinforces it. The organisations realising value are those that view AI as an extension of their digital backbone, not a shortcut around it.

Practical opportunities to close the maturity gap

1. Strengthening compliance and quality
AI can transform quality management by moving from reactive responses to predictive control. To do so responsibly, organisations must prioritise data integrity, standardised processes, clear data ownership and validation practices aligned to AI guidance

2. Accelerating R&D and insight generation
AI has the potential to restructure R&D timelines rather than just trimming them. By scanning vast data sets, AI can pinpoint new therapeutic targets, predict toxicity early and optimise trials, reducing costly late stage failures. Success depends on harmonised, high quality data and clear ownership, often starting with a robust data readiness assessment

3. Building supply chain resilience
AI-enabled demand sensing, risk prediction and scenario modelling can improve reliability across internal and CMO networks. These capabilities depend on trusted data and standardised processes across the end-to-end supply chain

4. Enhancing go-to-market and customer engagement
AI supports more personalised engagement across commercial and medical functions when customer, product and regulatory data are aligned. Strong governance remains critical to ensure traceability, content control and compliance.

Turning the maturity gap into an advantage

AI represents one of the most powerful catalysts for change in pharma – but only for organisations prepared to use it responsibly.

Leaders who view AI as a business transformation, rather than isolated innovation, will be best positioned to turn AI into a source of sustained advantage.

Those that do not risk falling further behind in an industry where speed, trust and precision are increasingly non-negotiable.